Core Viewpoint - Changlian Co., Ltd. (603648.SH) has signed an investment agreement with Shanghai Waigaoqiao Biopharmaceutical Industry Development Co., Ltd. to establish a joint venture named Shanghai Changlian Baifu Pharmaceutical Co., Ltd. [1] Group 1 - The investment agreement was signed on November 12, 2025, with Changlian Co. contributing 30 million yuan, which represents 60% of the new company's registered capital [1] - Shanghai Waigaoqiao Biopharmaceutical will contribute 20 million yuan, accounting for 40% of the registered capital [1] - Both parties will collectively hold 100% of the new company's registered capital [1]

证券代码：603648 证券简称：畅联股份 公告编号：2025-027 上海畅联国际物流股份有限公司 二、本次对外投资进展情况 2025 年 11 月，公司与生物医药公司正式签署《出资协议》，主要内容如下： （一）出资协议签署主体 关于对外投资暨关联交易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 投资标的名称 | 上海畅联百福医药有限公司 | | --- | --- | | 投资金额（万元） | 3,000 万元 | | 投资进展情况 | 正式签署协议 | | 特别风险提示（如有） | 无 | 一、对外投资基本情况 经上海畅联国际物流股份有限公司（以下简称"公司"或"畅联股份"） 第四届董事会第十二次会议、第四届监事会第十次会议、第四届董事会审计委 员会第十三次会议、第四届董事会独立董事专门会议第四次会议审议通过，同 意公司与上海外高桥生物医药产业发展有限公司（以下简称"生物医药公司"） 合资新设上海畅联百福医药有限公司（以下简称"畅联百福"或"新公司"）， 具 体 内 容 详 见 公 司 ...

Core Viewpoint - The company Changlian Co., Ltd. (stock code: 603648) announced that its general manager Xu Feng and deputy general manager Chen Wenye plan to reduce their shareholdings through centralized bidding transactions, indicating a potential shift in insider ownership and possible implications for investor sentiment [1] Summary by Categories Shareholding Reduction - Xu Feng, the general manager, intends to reduce his holdings by up to 2.0652 million shares, which represents 0.57% of the company's total share capital [1] - Chen Wenye, the deputy general manager, plans to reduce his holdings by up to 736,400 shares, accounting for 0.20% of the company's total share capital [1] Timeline and Pricing - The reduction plan is set to be implemented between December 4, 2025, and March 3, 2026 [1] - The selling price will be determined based on market conditions at the time of the transaction [1] Reason for Reduction - The stated reason for the shareholding reduction is personal financial needs [1] Source of Shares - The shares to be reduced are from those held prior to the company's initial public offering and have already been released from restrictions [1]

格隆汇11月12日丨畅联股份(603648.SH)公布,自本公告发布之日起十五个交易日后的三个月内，即2025 年12月4日至2026年3月3日，公司董事、总经理徐峰先生计划通过上海证券交易所交易系统集中竞价交 易方式进行减持，拟减持不超过206.52万股公司股份,占公司总股本的0.57%；公司董事、副总经理陈文 晔女士计划通过上海证券交易所交易系统集中竞价交易方式进行减持，拟减持不超过73.64万股公司股 份,占公司总股本的0.20%。减持价格视市场价格确定。 ...

Summary of Key Points Core Viewpoint - Changlian Co., Ltd. (603648.SH) announced plans for share reduction by its executives, indicating potential changes in insider ownership and market sentiment [1] Group 1: Share Reduction Plans - The company's General Manager, Mr. Xu Feng, plans to reduce his holdings by up to 2.0652 million shares, representing 0.57% of the total share capital [1] - The company's Deputy General Manager, Ms. Chen Wenye, intends to reduce her holdings by up to 736,400 shares, accounting for 0.20% of the total share capital [1] - The share reduction will be executed through centralized bidding on the Shanghai Stock Exchange, with the selling price determined by market conditions [1]

Core Viewpoint - Changlian Co., Ltd. (603648.SH) has signed an investment agreement with Shanghai Waigaoqiao Biopharmaceutical Industry Development Co., Ltd. to establish a joint venture named Shanghai Changlian Baifu Pharmaceutical Co., Ltd. [1] Group 1 - The investment agreement was signed on November 12, 2025, and the new company will be established with a registered capital structure where Changlian Co. will contribute 30 million yuan, representing 60% of the total capital [1] - Shanghai Waigaoqiao Biopharmaceutical will contribute 20 million yuan, accounting for 40% of the registered capital [1] - Both parties will collectively hold 100% of the new company's registered capital [1]

畅联股份公告，截至本减持计划披露日，董事、总经理徐峰持有公司472.04万股，占1.30%；董事、副 总经理陈文晔持有168.32万股，占0.46%。自公告发布之日起十五个交易日后的三个月内，即2025年12 月4日至2026年3月3日，徐峰拟以集中竞价方式减持不超过206.52万股，占0.57%；陈文晔拟以集中竞价 方式减持不超过73.64万股，占0.20%。减持价格视市场价格确定，若期间公司发生送股、资本公积金转 增股本、配股等事项，拟减持数量将相应调整。 ...

Core Viewpoint - Changlian Co., Ltd. announced the completion of a share reduction plan by Jiarong Investment, which sold 3,624,100 shares, accounting for 1% of the company's total share capital as of November 10, 2025 [1] Company Summary - Jiarong Investment reduced its holdings through centralized bidding transactions during the designated period [1] - As of the announcement date, Changlian's revenue composition for the year 2024 was 99.99% from supply chain management and 0.01% from other businesses [1] - The current market capitalization of Changlian Co., Ltd. is 4 billion yuan [1]

| 一、减持主体减持前基本情况 | | --- | 证券代码：603648 证券简称：畅联股份 公告编号：2025-026 上海畅联国际物流股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况 本次减持计划实施前，嘉融投资有限公司（以下简称"嘉融投资"）持 有上海畅联国际物流股份有限公司（以下简称"公司"）股份 10,720,855 股，占公司目前总股本的 2.96%。上述股份全部为公司首次公开发行股 票前已持有的股份，该部分股份已于 2018 年 9 月 13 日解除限售并上 市流通。 减持计划的实施结果情况 2025 年 11 月 10 日，公司收到嘉融投资《关于减持股份结果的告知函》。 在本次减持计划期间，嘉融投资通过集中竞价交易方式减持 3,624,100 股，占公司目前总股本的比例为 1%。截至 2025 年 11 月 10 日，嘉融投 资披露的减持时间区间届满，本次减持计划完成。 公司接到嘉融投资的通知，根据本次已披露的减持计划，嘉融投资总 ...

Group 1 - The core point of the article is that Changlian Co., Ltd. (603648.SH) has completed a share reduction plan initiated by Jiarong Investment, which involved the reduction of 3.6241 million shares, accounting for 1% of the company's total share capital as of November 10, 2025 [1] Group 2 - Jiarong Investment executed the share reduction through centralized bidding transactions [1] - The share reduction plan was officially completed on November 10, 2025, marking the end of the disclosed reduction period [1]